| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Center for Reproductive Sciences* and the Department of Pathology, University of California at San Francisco, San Francisco, California; the Department of Molecular Oncology, Genentech Incorporated, South San Francisco, California; and the Fox Chase Cancer Center, Philadelphia, Pennsylvania
Ovarian cancer is characterized by rapid growth of solid intraperitoneal tumors and production of large volumes of ascites. Our previous studies of intraperitoneal ovarian carcinoma in an athymic mouse model demonstrated that a monoclonal antibody (mAb) to human vascular endothelial growth factor (VEGF) could prevent ascites formation. Although ascites was almost completely inhibited, tumor burden was variably reduced. To develop more effective therapy, we assessed the combination of a human VEGF mAb plus paclitaxel. Four groups of female athymic nude mice were inoculated intraperitoneally with OVCAR3 cells. Two weeks after inoculation, one group was treated with a human VEGF mAb intraperitoneally twice weekly plus paclitaxel intraperitoneally three times weekly for 6 weeks. The second group was treated with VEGF mAb alone. The third group was treated with paclitaxel alone. The remaining group was treated with vehicle only. Tumor burden in the VEGF mAb plus paclitaxel and paclitaxel alone groups was reduced by 83.3% and 85.7% and 58.5% and 59.5%, respectively, in two separate experiments, compared to controls. VEGF mAb alone caused no significant decrease in tumor burden, nor did treatment of mice inoculated intraperitoneally with HEY-A8 cells, a non-VEGF-secreting ovarian cell line. Virtually no ascites developed in the combined treatment group or the group treated with VEGF mAb alone. Paclitaxel alone reduced ascites slightly, but not significantly. Morphological studies demonstrated that VEGF immunoneutralization enhanced paclitaxel-induced apoptosis in these human ovarian cancers. Thus, combination therapy with inhibitors of VEGF plus paclitaxel may be an effective way to markedly reduce tumor growth and ascites in ovarian carcinoma.
This article has been cited by other articles:
 |
|
 |
|
  D. K. Shah, B. S. Shin, J. Veith, K. Toth, R. J. Bernacki, and J. P. Balthasar Use of an Anti-Vascular Endothelial Growth Factor Antibody in a Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 580 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kuk, V. Kulasingam, C. G. Gunawardana, C. R. Smith, I. Batruch, and E. P. Diamandis Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers Mol. Cell. Proteomics, April 1, 2009; 8(4): 661 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mabuchi, Y. Terai, K. Morishige, A. Tanabe-Kimura, H. Sasaki, M. Kanemura, S. Tsunetoh, Y. Tanaka, M. Sakata, R. A. Burger, et al. Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model Clin. Cancer Res., December 1, 2008; 14(23): 7781 - 7789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Belotti, C. Calcagno, A. Garofalo, D. Caronia, E. Riccardi, R. Giavazzi, and G. Taraboletti Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion Mol. Cancer Res., April 1, 2008; 6(4): 525 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Burger, M. W. Sill, B. J. Monk, B. E. Greer, and J. I. Sorosky Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., November 20, 2007; 25(33): 5165 - 5171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tabernero The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents Mol. Cancer Res., March 1, 2007; 5(3): 203 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-P. Gerber, X. Wu, L. Yu, C. Wiesmann, X. H. Liang, C. V. Lee, G. Fuh, C. Olsson, L. Damico, D. Xie, et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies PNAS, February 27, 2007; 104(9): 3478 - 3483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sawada, A. R. Radjabi, N. Shinomiya, E. Kistner, H. Kenny, A. R. Becker, M. A. Turkyilmaz, R. Salgia, S. D. Yamada, G. F. Vande Woude, et al. c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion Cancer Res., February 15, 2007; 67(4): 1670 - 1679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Horsman and D. W. Siemann Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies Cancer Res., December 15, 2006; 66(24): 11520 - 11539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hu, N. Ferrara, and R. B. Jaffe Paracrine VEGF/VE-Cadherin Action on Ovarian Cancer Permeability. Experimental Biology and Medicine, November 1, 2006; 231(10): 1646 - 1652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jones-Bolin, H. Zhao, K. Hunter, A. Klein-Szanto, and B. Ruggeri The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Mol. Cancer Ther., July 1, 2006; 5(7): 1744 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Narita, J. Staub, J. Chien, K. Meyer, M. Bauer, A. Friedl, S. Ramakrishnan, and V. Shridhar HSulf-1 Inhibits Angiogenesis and Tumorigenesis In vivo. Cancer Res., June 15, 2006; 66(12): 6025 - 6032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hossein Pourgholami, Z. Yan Cai, Y. Lu, L. Wang, and D. Lawson Morris Albendazole: a Potent Inhibitor of Vascular Endothelial Growth Factor and Malignant Ascites Formation in OVCAR-3 Tumor-Bearing Nude Mice. Clin. Cancer Res., March 15, 2006; 12(6): 1928 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kim, I.-Y. Park, J. Lim, Y. Kim, K. T. Han, W. H. Chung, and K. Han Antitumor and Normal Cell Protective Effect of PKC412 in the Athymic Mouse Model of Ovarian Cancer Ann. Clin. Lab. Sci., January 1, 2006; 36(4): 455 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Said and K. Motamed Absence of Host-Secreted Protein Acidic and Rich in Cysteine (SPARC) Augments Peritoneal Ovarian Carcinomatosis Am. J. Pathol., December 1, 2005; 167(6): 1739 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hu, J. Hofmann, J. Holash, G. D. Yancopoulos, A. K. Sood, and R. B. Jaffe Vascular Endothelial Growth Factor Trap Combined with Paclitaxel Strikingly Inhibits Tumor and Ascites, Prolonging Survival in a Human Ovarian Cancer Model Clin. Cancer Res., October 1, 2005; 11(19): 6966 - 6971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Venook Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer Oncologist, April 1, 2005; 10(4): 250 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Hicklin and L. M. Ellis Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis J. Clin. Oncol., February 10, 2005; 23(5): 1011 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-P. Gerber and N. Ferrara Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies Cancer Res., February 1, 2005; 65(3): 671 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. X. Chen Expanding the Clinical Development of Bevacizumab Oncologist, June 1, 2004; 9(suppl_1): 27 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Byrne, L. Ross, J. Holash, M. Nakanishi, L. Hu, J. I. Hofmann, G. D. Yancopoulos, and R. B. Jaffe Vascular Endothelial Growth Factor-Trap Decreases Tumor Burden, Inhibits Ascites, and Causes Dramatic Vascular Remodeling in an Ovarian Cancer Model Clin. Cancer Res., November 15, 2003; 9(15): 5721 - 5728. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
